DarioHealth (DRIO) reported a third-quarter loss of $0.73 per share, missing the -$0.68 consensus by 7.4%. Revenue of $5.31 million beat the $5.2 million estimate by 2.1% and grew 6.1% year over year. That was the company's first year-over-year revenue gain after a decline in the second quarter. On paper, earnings improved 55.2% from a year ago. The bigger story, however, came from the call: management quietly pushed back its key timelines. Breakeven is now framed for 2028, and the $13.1 million of contracted and late-stage ARR will convert gradually across 2027 and into 2028. That is the central tension. Near-term revenue finally turned up, while the payoff that justifies the strategy moved further out.

The quality of the quarter deserves scrutiny. The per-share comparison is flattered by the capital structure:

• **Share count:** weighted average shares rose to 12.1 million from 3.1 million.
• **Prior-year charge:** the year-ago loss attributable to common shareholders included an $8.4 million deemed dividend.

The actual net loss narrowed more modestly, to $8.8 million from $10.5 million.

The revenue growth also came from the less attractive part of the model:

• **Consumer:** direct-to-consumer sales jumped about 48% and now make up 53% of revenue, up from 38%.
• **Services:** revenue fell to $2.55 million from $3.21 million.
• **Hardware:** consumer hardware climbed to $2.76 million from $1.80 million.
• **Enterprise:** B2B and B2B2C revenue declined as legacy Twill contracts were not renewed, partly offset by channel growth.

The recurring, roughly 80%-margin B2B2C engine that management wants to scale is not yet what is driving the top line.

Margins and costs moved the wrong way sequentially. GAAP gross margin slipped to 59.2% from 61.7% in the second quarter. Part of that decline is mechanical, since the IEEPA tariff refund benefit fell to about $0.1 million from $0.4 million. Operating expenses rose 16% sequentially to $11.2 million, largely because stock-based compensation climbed to $2.2 million from $0.6 million. Year over year, cost discipline is real: operating expenses fell 10% and the operating loss improved 15% to $8.0 million. Even so, the non-GAAP operating loss of $5.3 million was flat with the prior quarter. That is hard to square with the sharp 2026 narrowing management outlined earlier in the year.

The call kept a credible commercial story intact:

• **Channel wins:** Amwell delivered a third state health plan, a New Jersey ASO book of about 1.5 million covered lives. Additional channel opportunities cover 100,000+ and roughly 250,000 lives.
• **Channel growth:** channel revenue is tracking at 2x year over year, and management hinted that another large channel partner is close to signing.
• **DarioIQ:** the AI engagement system now shows measured uplift of up to about 14% in engagement-based ARR, at the high end of the 10%-15% expectation management set in the second quarter.
• **GLP-1:** a national health plan is working with Dario to bring GLP-1 therapy delivery into its member marketplace.
• **Leadership:** new chairman John Palombo brings a consumer/payer convergence framing.
• **Outlook:** the CFO said he is comfortable with 2027 consensus.

The execution record undercuts some of that optimism:

• **ARR conversion keeps slipping.** It has moved from "primarily second-half 2026" to "majority 2027" to now stretching into 2028, while the ARR figure itself has barely moved.
• **ASO deals convert slowly.** About 40% of ARR comes from these health plan agreements, and New Jersey revenue is not expected until the back half of 2027.
• **New products are later than signaled.** Dario Women and Dario Sleep revenue moved from the fourth quarter to January 1, 2027 go-lives.
• **The strategic review went unmentioned.** The sale or merger process, prominent on earlier calls, did not come up.
• **GLP-1 coverage is uncertain.** Employers pulling back on GLP-1 coverage add risk to that opportunity.

The balance sheet makes the delayed breakeven more consequential. Cash and short-term deposits stand at $31.2 million against a $31.2 million long-term loan. Nine-month operating cash burn was $17.6 million. Shares outstanding rose to 11.2 million from 6.9 million at year-end after roughly $22.8 million in equity raised. With breakeven now a 2028 event, bears have legitimate ammunition on runway and further dilution.

The market had already delivered a harsh verdict before the report. Shares fell from a $7.34 open after the August release to $2.13, a 71% decline. That leaves the stock about 71% below its $7.39 200-day moving average and roughly 74% below the inter-earnings high of $8.06 set August 21. It hit a 52-week low of $1.70 on November 10 and entered the print about 25% off that level. Price and AVWAP trend readings remain negative. Investor sentiment, meanwhile, improved sharply, from -0.74 to roughly neutral at -0.03. Expectations appear to have reset from deeply pessimistic to cautious, which may explain why a modest revenue beat could find a receptive audience.

The bottom line is that DarioHealth delivered its first year-over-year revenue growth and a growing channel pipeline, but the growth came mainly from lower-margin consumer hardware. The more important forward markers, ARR conversion, new-product revenue and breakeven, all moved later. After a 71% drawdown, sentiment has already washed out. The burden now shifts to converting signed lives into recognized B2B2C revenue before the cash position forces another reckoning.